Category: Drug Side Effects

Prevacid Class Action Lawsuit

Prevacid Class Action Lawsuit

Update: Long-Term PPI Use Linked to Doubled Risk for Gastric Cancer December 1, 2017 – Use of a proton-pump inhibitor like Prevacid after Helicobacter pylori eradication more than doubles your risk for stomach cancer, according to a new study published...

Aciphex Class Action Lawsuit

Aciphex Class Action Lawsuit

Our firm is investigating potential cases involving the heartburn drug, Aciphex. It has been linked to side effects such as chronic kidney disease, bone fractures, renal failure, stomach cancer, heart attacks and more.

Prilosec Class Action Lawsuit

Prilosec Class Action Lawsuit

Update: Common Heartburn Drugs Linked to Doubled Risk of Stomach Cancer December 1, 2017 – Prilosec and other acid rerflux drugs from the Proton pump inhibitor class have been linked to a greater-than-doubled risk of developing stomach cancer, a new...

sc-no-longer-accepting-cases
Taxotere Class Action Lawsuit

Taxotere Class Action Lawsuit

Update: Dozens of Victims of Taxotere Side Effects File Suit in Cook County Circuit Court January 22, 2018 – A number of women who claim their hair fell out and never grew back due to a side effect of Taxotere...

Tradjenta Class Action Lawsuit

Tradjenta Class Action Lawsuit

Update: Diabetes Drugs Linked to Rhabdomyolysis December 1, 2017 – Tradjenta and other diabetes drugs in its class have been associated with a rare, life-threatening muscular disease called rhabdomyolysis, according to the FDA Adverse Event Reporting System (FAERS). Rhabdomyolysis occurs...

Jentadueto Class Action Lawsuit

Jentadueto Class Action Lawsuit

FDA Investigating Link Between DPP-4 Inhibitors & Rhabdomyolysis December 1, 2017 – FDA has received reports of rhabdomyolysis, a syndrome caused by injury to skeletal muscle, in patients with type 2 diabetes who have taken Jantadueto and other DPP-4 inhibitors....

Kazano Class Action Lawsuit

Kazano Class Action Lawsuit

Update: FDA Warning on Rhabdomyolysis Risk with Kazano December 1, 2017 – The U.S. Food & Drug Administration has recently obtained data indicating that Kazano and other DPP-4 inhibitors may increase the risk for rhabdomyolysis, a severe muscular disease characterized...